Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
IrelandIPO:
21 October 1992Website:
http://www.trinitybiotech.comNext earnings report:
04 April 2025Last dividends:
05 June 2015Next dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:48:15 GMTDividend
Analysts recommendations
Institutional Ownership
TRIB Latest News
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for the quarter ended September 30, 2024. Key Highlights and Developments Continued Revenue and Profitability Improvements Year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in the operating loss (before restructuring and impairment charges) to $2.2 million from $4.5m in Q3 2023, a 51% improvement.
Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Officer Louise Tallon - Chief Financial Officer Conference Call Participants James Sidoti - Sidoti & Company Paul Nouri – Noble Equity Funds Operator Greetings. Welcome to the Trinity Biotech Third Quarter 2024 Earnings Conference Call.
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus' groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test.
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024.
TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management.
-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women-
TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology. Earlier this year Trinity Biotech was granted a European patent (EP3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of Trinity Biotech's glucose biosensor. Trinity Biotech intends to use this breakthrough process to stabilise and improve the functionality of the glucose biosensor in its next generation continuous glucose monitor (CGM) technology.
DUBLIN, Ireland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV. As a result of this strong demand and the successful scaling of production capacity, the Company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 million, up from $8 million previously.
- 1(current)
What type of business is Trinity Biotech?
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
What sector is Trinity Biotech in?
Trinity Biotech is in the Healthcare sector
What industry is Trinity Biotech in?
Trinity Biotech is in the Medical Devices industry
What country is Trinity Biotech from?
Trinity Biotech is headquartered in Ireland
When did Trinity Biotech go public?
Trinity Biotech initial public offering (IPO) was on 21 October 1992
What is Trinity Biotech website?
https://www.trinitybiotech.com
Is Trinity Biotech in the S&P 500?
No, Trinity Biotech is not included in the S&P 500 index
Is Trinity Biotech in the NASDAQ 100?
No, Trinity Biotech is not included in the NASDAQ 100 index
Is Trinity Biotech in the Dow Jones?
No, Trinity Biotech is not included in the Dow Jones index
When was Trinity Biotech the previous earnings report?
No data
When does Trinity Biotech earnings report?
The next expected earnings date for Trinity Biotech is 04 April 2025